Vladislav SolovevPartner & Head of Research

November 6, 2026 · 7 min read

OPM Backsolve vs PWERM: Key Differences Explained

Two ways to value the common stock of a private company. How each one works, when each fits and what it means for your stock options.

  • Valuation
1.0The short answer

OPM vs PWERM comes down to where the value starts. An OPM backsolve starts from the price investors just paid in a funding round and works back to the value of every share class. PWERM starts from possible exits, such as an IPO or a sale, and weighs each by its chance. The backsolve suits a company far from an exit. PWERM suits one with a clear exit in view.

If you hold stock options in a private company, these methods set the value of your common stock. That value becomes the exercise price on new grants, so it affects what you pay later. If you invest in a startup, it explains why common stock is valued far below the price you paid for preferred.

$1.00 → $0.25

Inozyme’s preferred share price in November 2018 and its common stock value from an OPM backsolve that month

11.2018 · Inozyme Pharma Form S-1

$0.27 → $0.37

Inozyme’s common stock value before and after it switched to a hybrid with an IPO scenario

05.31.2019 and 03.31.2020 · Inozyme Pharma Form S-1

12 months

Maximum age of an independent appraisal that US tax rules presume reasonable

Current rule · Treas. Reg. §1.409A-1

20%

Extra federal tax, plus interest, on pay caught by a Section 409A failure

Current law · 26 U.S.C. §409A

2.0Side by side

What Is the Main Difference Between OPM Backsolve and PWERM?

The table compares the two methods on what each is, who uses it, its inputs, legal and tax treatment, the main risk, how it relates to liquidity and a typical example. Both methods answer the same question. They answer it from different starting points.

What it is
OPM backsolveAn option pricing method (OPM) that solves for the company value implied by a recent sale of its shares.
PWERMThe probability-weighted expected return method: a scenario method that values each share class at several possible exits.
Where value starts
OPM backsolveThe price of the latest round, usually preferred stock sold at arm’s length.
PWERMForecast exit values, such as an IPO price or a sale price.
How it splits value
OPM backsolveTreats each share class as a call option on the whole company, with strike prices set by the liquidation preferences.
PWERMRuns the payout to each class in each scenario, weights by probability and discounts to today.
Key inputs
OPM backsolveRound price and terms, time to an exit, volatility of similar public stocks, the risk-free rate.
PWERMScenarios, their probabilities, exit values, timing and a risk-adjusted discount rate.
Who uses it
OPM backsolveValuation firms preparing 409A appraisals and stock compensation figures, mostly for earlier-stage companies.
PWERMThe same firms, mostly when an IPO or sale is planned and its terms can be estimated.
Legal and tax treatment
OPM backsolveAccepted for 409A if it is reasonable. The rules list recent arm’s-length sales of the stock as a factor.
PWERMAccepted for 409A on the same test. The rules name no method, so the choice must fit the facts.
Main risk
OPM backsolveThe round may not reflect the common stock, and volatility and timing guesses move the result.
PWERMProbabilities and exit values are judgment calls that are hard to support far from an exit.
Liquidity
OPM backsolveFits when the exit path is unclear or years away.
PWERMFits when a specific exit is near and can be modeled.
Typical example
OPM backsolveInozyme Pharma, valuations from 2017 through May 2019.
PWERMInozyme Pharma, March 2020, as a hybrid with an IPO scenario before its listing.

The backsolve anchors on what investors paid. PWERM anchors on what an exit might pay. A hybrid uses both

As of November 2026 · Treas. Reg. §1.409A-1(b)(5)(iv)(B); Inozyme Pharma Form S-1 (07.02.2020). US rules; methods vary by appraiser.

3.0How each works

How the Backsolve and PWERM Reach a Number

OPM Backsolve

The OPM backsolve begins with a fact. Investors just bought preferred stock at a known price. The appraiser builds an option model of the whole cap table. Each class is treated as a call option on the company’s value, a right that pays only above a certain level. The appraiser then searches for the total equity value at which the model gives that exact preferred price.

Once the total is found, the model splits it among the classes. Common stock sits behind the liquidation preference, so it gets less per share. A discount for lack of marketability then lowers it further, because common shares cannot be sold easily.

PWERM

PWERM begins with a forecast. The appraiser lists the ways the company could end: an IPO, a sale or a wind-down. For each one, it estimates the exit value and the payout to each class. It weights the payouts by probability and discounts them to today.

An illustrative case, with invented numbers. A company expects one of three outcomes in two years:

  • IPO, 50% chanceCommon stock worth $12 a share
  • Sale, 35% chanceCommon stock worth $6 a share
  • Wind-down, 15% chanceCommon stock worth $0
  • ResultWeighted value $8.10 → $5.18 after a 25% yearly discount rate → $4.15 after a 20% marketability discount

A hybrid method is a PWERM in which one scenario is valued with an OPM. Inozyme used one in March 2020. It valued an IPO scenario from recently listed peers and an unspecified exit with a backsolve.

4.0Investors and employees

Which Is Better for Investors or Employees?

Neither method favors one side by design. The test is whether the method fits the company’s facts. A backsolve fits when a fresh round exists and no exit is planned. PWERM fits when bankers are hired and an IPO window can be modeled.

For employees, the method matters through the exercise price. A lower common value means a lower price on new options. A value that is too low invites tax trouble, so appraisers must defend every input. For investors, the method explains the gap between their preferred price and the common value.

Inozyme shows the gap. It sold Series A preferred at $1.00 a share on November 8, 2018. Its appraisal as of November 30, 2018 valued the common stock at $0.25. As an IPO came into view, it moved to a hybrid. The common value rose from $0.27 in May 2019 to $0.37 in March 2020.

5.0Tax

How the Tax Treatment Compares

The tax rules are the same for both methods. Under Section 409A, private company stock must be valued by the reasonable application of a reasonable method. The regulations list factors such as the company’s assets, its future cash flows and recent arm’s-length sales of its stock. They do not name the OPM or PWERM.

An independent appraisal dated no more than 12 months before a grant is presumed reasonable. The IRS can overturn it only by showing the method, or how it was applied, was grossly unreasonable. This appraisal is the 409A valuation. To keep that presumption, a company refreshes its appraisal at least every 12 months.

If options are priced below fair market value, they can fall under Section 409A. The holder then owes income tax early, interest and an extra 20% tax. The method choice does not change these rules. It changes the number the rules are applied to.

6.0Pros and cons

OPM Backsolve vs PWERM Pros and Cons: A Verdict on Each

OPM Backsolve

For
It starts from a real price paid by outside investors. It needs no forecast of exit values or their odds. It handles complex share classes in one model.
Against
The round may include terms the common stock lacks. Volatility and time-to-exit guesses can move the result a lot. It ignores a known exit plan.

Verdict: the backsolve is the natural choice soon after a priced round, when no exit is in sight. Its strength is the anchor in a real transaction. Its weakness is that the anchor ages, and a stale round gives a stale value.

PWERM

For
It shows how each share class fares in each exit. It reflects a planned IPO or sale directly. Its logic is easy to follow.
Against
Every probability and exit value is a judgment. Far from an exit, the scenarios are hard to support. Small changes in the odds can swing the result.

Verdict: PWERM fits a company preparing an IPO or a sale. The closer the exit, the easier the scenarios are to defend. Many appraisers use a hybrid at that stage, as Inozyme did, to keep a backsolve for the case where the IPO does not happen.

Key point

Use the backsolve when a recent round is the main evidence of value. Use PWERM or a hybrid when a specific exit is close enough to model.

7.0For you

What the Method Means for Your Shares

If you receive options, ask which method the latest appraisal used and its date. A value more than 12 months old loses its presumption. A new round or a planned IPO can also make it stale. For how the common value relates to the round price, see 409A valuation vs preferred price.

If you buy shares in a secondary sale, remember that a 409A value is a tax figure. Your price is set by the deal. For the wider toolkit, see private company valuation and common stock vs preferred stock.

Common Mistakes

  • Reading the 409A value as a market priceIt values common stock for tax and accounting. Buyers in a secondary sale may pay more or less.
  • Expecting common to equal the preferred pricePreferred stock is paid first in an exit. Inozyme’s common was valued at a quarter of its preferred price.
  • Treating one method as the IRS’s choiceThe rules require a reasonable method. They do not name either one.
  • Ignoring the dateA value is reasonable for 12 months at most. A new round or IPO plan can age it sooner.
8.0Terms

The Terms This Page Uses

OPM backsolve
A method that finds the total company value implied by a recent round price, then splits it among share classes with an option model.
PWERM
The probability-weighted expected return method. It values share classes across possible exits, weighted by probability and discounted to today.
Hybrid method
A PWERM in which one scenario is valued with an option pricing method.
Option pricing method (OPM)
A model that treats each share class as a call option on the whole company’s value.
Call option
A right that has value only when the underlying value rises above a set level.
Liquidation preference
The right of preferred holders to be paid back before common holders in a sale or wind-down.
Discount for lack of marketability
A reduction for shares that cannot be sold easily, applied after the method sets a value.
409A valuation
An appraisal of private company common stock used to price stock options under US tax rules.
Arm’s-length transaction
A sale between unrelated parties, each acting in its own interest.
9.0Questions

What People Ask About OPM and PWERM

No. The Section 409A regulations require a reasonable method applied reasonably. They list factors to consider, including recent arm’s-length sales of the stock, but they name neither method.

Yes. Inozyme valued its common stock with a backsolve through May 2019. By March 2020, ahead of its IPO filing, it used a hybrid with an IPO scenario.

Preferred holders are paid first in an exit, and common shares are hard to sell. Both methods capture the first point. A marketability discount captures the second.

It is a PWERM in which one scenario uses an option model. A common setup values an IPO scenario directly and an uncertain exit with a backsolve.

It depends on events. An appraisal is presumed reasonable for up to 12 months. A new round, a planned IPO or a big change in the business can make it stale sooner.

10.0Sources

Where Every Rule on This Page Comes From

Figures were last checked on November 6, 2026. The rules are United States federal tax rules. Each appraisal follows its own assumptions, and a company’s figures are the ones in its own filings.

  1. 01Code of Federal Regulations (Cornell LII)Current ruleTreas. Reg. §1.409A-1(b)(5)(iv)(B): reasonable valuation method, factors incl. recent arm’s-length transactions, 12-month limit and appraisal presumption
  2. 02United States Code (Cornell LII)Current law26 U.S.C. §409A(a)(1): income inclusion, interest and additional 20% tax
  3. 03Inozyme Pharma, Inc. (SEC EDGAR)07.02.2020Form S-1: backsolve and OPM through 05.31.2019, hybrid method as of 03.31.2020, common values $0.13 to $0.37, Series A at $1.00
  4. 04AICPA & CIMA01.16.2026Working draft of the updated guide on valuing private company equity issued as compensation

This page explains how a market works. It is not investment advice, not a recommendation of any security, strategy or company, and not an offer to sell or a solicitation to buy anything. Private companies may never list or be acquired, positions in them can be illiquid for years, and the entire amount invested can be lost. Figures are accurate as of the dates shown and change. Requirements for investor status, and the tax treatment of a private holding, differ by jurisdiction — the jurisdiction is named wherever this page discusses either. Prepared by the AXEVIL Capital research team.

What closed on the private market in the past two weeks

The rounds that priced, the tender offers that opened and the listings that filed — with the structure of each deal and the date on every figure. Written by the team that reads the paperwork.

Once every two weeks. One email, no sales sequence, unsubscribe in one click. By subscribing you agree that Axevil Capital, LLC will process your email to send the newsletter, as described in the Privacy Policy. Read the published archive first if you like.
San Francisco548 Market St, San Francisco, California, 94104, United States
DubaiThe One Tower, 23rd Floor, Office 13, Dubai, United Arab Emirates
AstanaOffice 338, 55/23 Mangilik El Avenue, Astana, Republic of Kazakhstan

Axevil Capital, LLC is a company (Delaware, #6832739) with legal address: 548 Market St, San Francisco, California, 94104, United States.

Axevil Capital, LLC has Exempt Reporting Adviser (ERA) status (SEC #802−126907).

The information presented on the website is for informational purposes only and:
— does not constitute an offer to buy or sell securities or other financial instruments;
— does not constitute an invitation to trade or provision of investment services;
— does not constitute individual investment advice.

The Company works exclusively with qualified investors who possess the necessary knowledge, experience, and financial capacity to assess risks and invest in high-risk instruments. This asset class involves elevated risks, volatility, and illiquidity. Investors must be prepared to accept the possibility of total loss of invested capital as well as lack of liquidity.

NOTIFICATION OF INVESTMENT RISKS AND STATUS OF THE COMPANY'S ACTIVITIES

FOR ALL INVESTORS GENERALLY:
The Company's activities focus on attracting investments in mature venture projects at the stage of sustainable business development, close to IPO exit.
The Company does not guarantee profit generation. Investments involve risks, including the possibility of returns below expectations, which cannot be guaranteed.

NOTICE TO INVESTORS IN THE UNITED STATES:
— Investment interest offerings are conducted as private placements and are not subject to registration under US securities laws.
— Available only to accredited investors.
— Such securities may have transfer and resale restrictions.
— Investments carry a high level of financial risk.
— Independent legal, tax, and financial consultation is strongly recommended before making investment decisions.

NOTICE TO RESIDENTS OF THE UNITED ARAB EMIRATES (UAE):
— Investment interest offerings are not public in the UAE.
— Directed only to qualified institutional investors.
— Interests are not registered or approved by the UAE Central Bank, SCA, or other regulators.

NOTICE TO RESIDENTS OF ITALY:
— Interest offerings are not authorized by Italian regulators under Decreto Legislativo No. 58/1998.
— Interests may not be offered, distributed, or sold to the general public.

NOTICE TO RESIDENTS OF THE UNITED KINGDOM:
— SPVs constitute unregulated collective investment schemes under FSMA 2000.
— Promotion is restricted and permitted only to "relevant persons" within the meaning of Financial Promotion Order 2005 (Articles 19(5), 49(2)(a)-(d)).
— Most standard protections of the UK regulatory system do not apply.
— Compensation under the UK Financial Services Compensation Scheme is not provided.

NOTICE TO RESIDENTS OF SWEDEN:
— The partnership is not an investment fund under the Swedish Investment Funds Act (2004:46).
— The offering is not subject to registration under the Swedish Financial Instruments Trading Act (1991:980).
— Interests are not approved and will not be approved by the Swedish Financial Supervisory Authority.

NOTICE TO RESIDENTS OF SWITZERLAND:
— SPVs are not approved by FINMA as foreign collective investment schemes under Article 120 CISA. Interests may not be publicly offered or distributed in Switzerland.
— SPVs are not regulated by Swiss authorities.
— Interests are available only to "qualified investors" under CISA or a limited circle of persons without public offering.
— By continuing, you confirm that:
1. You qualify as an accredited/qualified investor under the laws of your jurisdiction (e.g., in the U.S. an annual income exceeding $200,000 individually or $300,000 jointly, or net worth above $1 million, excluding primary residence).
2. You are legally permitted to access this information in your jurisdiction.
3. You understand that private investments involve a high degree of risk, including the risk of total loss of capital.

Axevil Capital 2021−2026 — All Rights Reserved